---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-307450"
form_type: "8-K"
ticker: "MPLT"
cik: "0001770069"
company_name: "MapLight Therapeutics, Inc."
filed_at: "2025-12-04T23:59:59+00:00"
generated_at: "2026-05-16T14:51:55.425695+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# MapLight reports Q3 net loss $29.4M; cash runway through 2027; Phase 2 readouts in 2026-2027

## Summary
- Net loss $29.4M vs $19.0M in Q3 2024; R&D spend $27.1M (up 61% YoY) on clinical trial costs.
- Cash & investments $227.2M at Q3 end; Oct IPO netted $269.8M, extending runway through 2027.
- Phase 2 ZEPHYR (schizophrenia, n=300) topline H2 2026; VISTA (Alzheimer's psychosis) topline H2 2027.
- ML-004 (autism) IRIS Phase 2 enrollment completed (~160 pts); topline results H2 2026.
- ML-021 (Parkinson's) IND-enabling studies H2 2026; ML-009 (GPR52 PAM) candidate nominated.

## SEC filing metadata
- accession: 0001193125-25-307450
- form_type: 8-K
- ticker: MPLT
- cik: 0001770069
- company_name: MapLight Therapeutics, Inc.
- filed_at: 2025-12-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770069/000119312525307450/0001193125-25-307450-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770069/000119312525307450/mplt-20251204.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-307450
- JSON: https://secwatch.observer/filing/0001193125-25-307450.json
- Plain text: https://secwatch.observer/filing/0001193125-25-307450.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.